image
Healthcare - Biotechnology - NASDAQ - US
$ 1.595
2.61 %
$ 452 M
Market Cap
-2.75
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ERAS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.59 USD, Erasca, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ERAS stock under the base case scenario is HIDDEN Compared to the current market price of 1.59 USD, Erasca, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ERAS stock under the best case scenario is HIDDEN Compared to the current market price of 1.59 USD, Erasca, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ERAS

image
$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-180 M OPERATING INCOME
-26.89%
-162 M NET INCOME
-29.28%
-109 M OPERATING CASH FLOW
-8.10%
-157 M INVESTING CASH FLOW
-71.69%
241 M FINANCING CASH FLOW
18486.64%
0 REVENUE
0.00%
-35.6 M OPERATING INCOME
0.23%
-31 M NET INCOME
3.93%
-31.6 M OPERATING CASH FLOW
-28.46%
34.3 M INVESTING CASH FLOW
51.50%
33 K FINANCING CASH FLOW
-95.88%
Balance Sheet Erasca, Inc.
image
Current Assets 309 M
Cash & Short-Term Investments 298 M
Receivables 0
Other Current Assets 10.5 M
Non-Current Assets 194 M
Long-Term Investments 142 M
PP&E 48.5 M
Other Non-Current Assets 3.03 M
59.36 %28.29 %9.66 %Total Assets$502.5m
Current Liabilities 31.4 M
Accounts Payable 468 K
Short-Term Debt 9.24 M
Other Current Liabilities 21.7 M
Non-Current Liabilities 47.6 M
Long-Term Debt 94.5 M
Other Non-Current Liabilities -46.9 M
11.69 %27.45 %119.63 %Total Liabilities$79.0m
EFFICIENCY
Earnings Waterfall Erasca, Inc.
image
Revenue 0
Cost Of Revenue 3.8 M
Gross Profit 0
Operating Expenses 180 M
Operating Income -180 M
Other Expenses -17.9 M
Net Income -162 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)0(4m)0(180m)(180m)18m(162m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-38.17% ROE
-38.17%
-32.17% ROA
-32.17%
-37.39% ROIC
-37.39%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Erasca, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)202020202021202120222022202320232024202420252025
Net Income -162 M
Depreciation & Amortization 3.8 M
Capital Expenditures -60 K
Stock-Based Compensation 27 M
Change in Working Capital 1.74 M
Others 23 M
Free Cash Flow -109 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Erasca, Inc.
image
Wall Street analysts predict an average 1-year price target for ERAS of $4.67 , with forecasts ranging from a low of $3 to a high of $6 .
ERAS Lowest Price Target Wall Street Target
3 USD 88.09%
ERAS Average Price Target Wall Street Target
4.67 USD 192.58%
ERAS Highest Price Target Wall Street Target
6 USD 276.18%
Price
Max Price Target
Min Price Target
Average Price Target
6666555544443333222211Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Erasca, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors. “Our RAS-targeting franchise continues to meaningfully advance, and now with clearance of our IND for ERAS-4001, we are excited to advance both ERAS-4001 and ERAS-0015 into the clinic ahead of our guidance,” said Jonathan E. globenewswire.com - 2 weeks ago
Erasca to Present at Upcoming Investor Conferences in June SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. globenewswire.com - 3 weeks ago
Erasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2025. “We are pleased with the pace and execution of our RAS-targeting franchise and its early entry into the clinic following the recent IND clearance for ERAS-0015 and IND filing for ERAS-4001,” said Jonathan E. globenewswire.com - 1 month ago
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-0015, a pan-RAS molecular glue with best-in-class potential for patients with RAS-mutant (RASm) solid tumors, and submission of an IND application for ERAS-4001, a potential first-in-class pan-KRAS inhibitor in KRAS-mutant (KRASm) solid tumors. The company also announced a strategic decision to pursue partnership opportunities for naporafenib, enabling a meaningful extension of cash runway guidance from the second half of 2027 to the second half of 2028. globenewswire.com - 1 month ago
Erasca to Present at the Bank of America Securities Health Care Conference SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor meetings. globenewswire.com - 1 month ago
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today presented new preclinical data reinforcing the best-in-class profiles of Erasca's RAS-targeting franchise at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The Company also presented potential first-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly, representing a new approach to block oncogenic RAS/MAPK pathway signaling. globenewswire.com - 1 month ago
Erasca, Inc.: Carving A Different Niche In RAS Signaling Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk. seekingalpha.com - 1 month ago
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025, in Chicago, Illinois. The abstracts will be available on the AACR 2025 meeting website. globenewswire.com - 2 months ago
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 globenewswire.com - 3 months ago
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings. globenewswire.com - 4 months ago
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors. seekingalpha.com - 4 months ago
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 4 months ago
8. Profile Summary

Erasca, Inc. ERAS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 452 M
Dividend Yield 0.00%
Description Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Contact 10835 Road to the Cure, San Diego, CA, 92121 https://www.erasca.com
IPO Date July 16, 2021
Employees 103
Officers Mr. Ebun S. Garner Esq., J.D. General Counsel & Corporate Secretary Mr. Brian L. Baker CPA, M.S. Senior Vice President of Finance Dr. Shannon R. Morris M.D., Ph.D. Chief Medical Officer Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & Chief Executive Officer Dr. David M. Chacko M.D. Chief Financial Officer & Chief Business Officer Dr. Michael D. Varney Ph.D. Chairman of Research & Development, Scientific Advisory Board Member and Director Dr. Nik Chetwyn Ph.D. Chief Operating Officer Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer Ms. Chandra D. Lovejoy M.S. Chief Regulatory Affairs Officer Dr. Robert Shoemaker Ph.D. Senior Vice President of Research